Technologies

Medical Sciences

Title:	A study for safety and efficacy of VELGRAFT containing Human Bone marrow derived Mesenchymal Stem Cell and Mesenchymal stem cell differentiated adipocytes as a skin substitute on wounds of Diabetic Foot Ulcers
Area:	Medical Sciences
Focus Area:	Devices and Diagnostics, Wound healing implant, Biopharma
Status:	Pre-commercilization stage (Phase-I clinical trials are completed and CDSCO application is under process, Phase-II trials will be initiated after CDSCO approval)
Social Benefits:	1. Indigenously developed and manufactured 2. Once developed will be Availability in the local market. 3. VELGRAFT is immunologically inert- ensuring well-tolerance and less rejection from the graft recipient. 4. Optimized cold transport system with real time monitoring and delivering in short duration. 5. Increased accessibility, and reduced turnaround time & cost.
Developing Agency:	Datt Mediproducts Private Limited, East of Kailash, New Delhi
Technology Readiness Index:	TRL 7

Brief Description

Description :

Velgraft is a biocompatible and biodegradable skin substitute, and all the constituents of Velgraft has been in medical use for many years and their trouble free records serves to underline the safety of this product. Mesenchymal stem cell has been used widely used for the treatment of many diseases and they have been proved to be non-immunogenic and non-tumorigenic. Additionally, cells contained in Velgraft are cultured in xenogeneic free medium, reducing risk of sensitivity to animal products. The flexible and porous matrix of Velgraft is comprised of natural polymers which help in reducing the healing time.